A practical reference on Cyclic AMP: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
| Property | Value | Notes |
|---|---|---|
| Appearance as powder | White to off-white solid | Minor batch-to-batch variation is normal |
| Solubility class | Soluble in water and aqueous buffers | Dissolution can be slowed by aggregates |
| Typical storage temperature | Minus 20 degrees Celsius or below | Protected from light and moisture |
| Storage after reconstitution | 2 to 8 degrees Celsius, short term | Longer holding requires freezing |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity and identity confirmation |
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
== Adverse events related to red blood cell transfusion == Adverse events related to transfusion in general may include allergic reactions such as anaphylaxis, infection, volume overload, and lung injury. With current screening methods, the risk of viral infections such as hepatitis C and HIV/AIDS are less than one in a million. With current testing methods in high-income countries the prevalence of transfusion-transmissible infections in blood donations is very low (median: HIV 0.002%, hepatitis B 0.02%, hepatitis C 0.007% and syphilis 0.02% in 2024). However, in low-income countries the risk of a blood donation being positive for HIV, hepatitis C or syphilis is up to 1%, and the risk of it being hepatitis B positive was approximately 2.8% in 2024. The differences relate to variations in eligible blood donors, whether the donation is paid or voluntary, non-remunerated, and the effectiveness of the system of educating and selecting donors. Adverse events related to transfusion of red blood cells are mainly linked to incompatibility issues or other transfusion reactions. Incompatible AB0 transfusion can be fatal. For patients with a previous transfusion reaction history, the risk of repeated adverse events can be mitigated by choosing the proper processing modification and/or red blood cell phenotype combination.
== Side effects == Side effects include sweating, palpitations, loss of consciousness and rarely convulsions due to severe hypoglycemia which may cause coma. If extreme symptoms are present, glucose should be given intravenously. In subjects with no adrenal reserve an Addisonian crisis may occur. For cortisol stimulation, the ACTH stimulation test has much less risk.
=== Wilson's disease === Wilson's disease is a rare autosomal (chromosome 13) recessive genetic disorder of copper transport that causes an excess of copper to build up in the liver. This results in liver toxicity, among other symptoms. The disease is now treatable. Wilson's disease is produced by mutational defects of a protein that transports copper from the liver to the bile for excretion. The disease involves poor incorporation of copper into ceruloplasmin and impaired biliary copper excretion and is usually induced by mutations impairing the function of the Wilson copper ATPase. These genetic mutations produce copper toxicosis due to excess copper accumulation, predominantly in the liver and brain and, to a lesser extent, in kidneys, eyes, and other organs. The disease, which affects about 1/30,000 infants of both genders, may become clinically evident at any time from infancy through early adulthood. The age of onset of Wilson's disease ranges from 3 to 50 years of age. Initial symptoms include hepatic, neurologic, or psychiatric disorders and, rarely, kidney, skeletal, or endocrine symptomatology. The disease progresses with deepening jaundice and the development of encephalopathy, severe clotting abnormalities, occasionally associated with intravascular coagulation, and advanced chronic kidney disease. A peculiar type of tremor in the upper extremities, slowness of movement, and changes in temperament become apparent.
=== Ecological crisis === Yemen's political instability has been compounded and partly caused by the severe ecological crisis in the country. As of 2023, the average Yemeni has access to only 86 m3 of renewable freshwater per year for all uses, (62 gallons per day) compared to a Middle Eastern regional average of approximately 631 m3, both of which are significantly below the internationally defined threshold for water stress of 1,700 m3 per capita per year. Yemen's groundwater is the main source of water in the country but the water tables have dropped severely, leaving the country without a viable source of water. For example, in Sanaa, the water table was 30 meters below surface in the 1970s but had dropped to 1200 meters below surface by 2012. The groundwater has not been regulated by Yemen's governments. Even before the revolution, Yemen's water situation had been described as increasingly dire with some environmental analysts warning that Yemen could be among the first countries to face extreme water scarcity if current trends continue. Agriculture in Yemen takes up about 90% of water in Yemen even though it only generates 6% of GDP - however a large portion of Yemenis are dependent on small-scale subsistence agriculture. Half of agricultural water in Yemen is used to grow khat, a narcotic that most Yemenis chew. This means that in such a water-scarce country as Yemen, where half the population is food-insecure, 45% of the water withdrawn from the ever-depleting aquifers is used to grow a crop that feeds nobody.
Sources: en.wikipedia.org
=== Extractable nuclear antigens === Extractable nuclear antigens (ENA) are a group of autoantigens that were originally identified as antibody targets in people with autoimmune disorders. They are termed ENA because they can be extracted from the cell nucleus with saline. The ENAs consist of ribonucleoproteins and non-histone proteins, named by either the name of the donor who provided the prototype serum (Sm, Ro, La, Jo), or the name of the disease setting in which the antibodies were found (SS-A, SS-B, Scl-70).
Equal treatment is a fundamental right in international law because it has been universally recognised that people should be judged by the content of their character, their skills and knowledge, and not irrelevant characteristics. An equal treatment claim under the Fair Work Act 2009 enables a complaint to the Fair Work Commission, similar to other labour rights. By contrast, claims under the Racial Discrimination Act 1975, the Sex Discrimination Act 1984, Disability Discrimination Act 1992 and Age Discrimination Act 2004 enable a separate path for claims to the Australian Human Rights Commission, created in 1986, which may resolve disputes by conciliation, or if that is unsuccessful claims can go to federal court. Within states, similar systems exist with a watchdog, and appeals to a Tribunal, for instance the Anti-Discrimination Board of NSW and then the NSW Civil and Administrative Tribunal, but claimants cannot bring proceedings at both federal and state level, and so must choose. The FWA 2009 section 27(1A) says that federal law does not exclude state anti-discrimination laws, meaning that greater protection can be provided by states where the federal government has not acted. Despite these rights to formal equality, structural problems (including unequal parental leave, and historic disadvantage) mean discrimination remains rife, so that the gender pay gap remains at 21.7% according to employer surveys, and the Indigenous pay gap is over 33%.
Verbena officinalis in the CalPhotos photo database, University of California, Berkeley "Verbena officinalis". Calflora. Berkeley, California: The Calflora Database. "Verbena officinalis". Plants for a Future.
The development of myasthenia gravis in people without myasthenia gravis appeared to be more likely in people over 60 years of age. Six non-statin cholesterol-lowering drugs, nicotinic acid, cholestyramine, colestipol, colesevelam, alirocumab, and evolocumab, have been used in people without causing or worsening myasthenia gravis. Beta blockers: Beta blockers (i.e., β-blockers) are drugs that block the binding of two stress hormones, epinephrine and norepinephrine, to their target beta receptors. They are used to decrease the heart rate, reduce the force of heart contractions, and relax blood vessels in order to lower blood pressure and reduce the workload on the heart. In one study the odds of an myasthenia gravis exacerbation after taking a beta blocker was increased 2.7-fold compared with people with myasthenia gravis not taking a beta blocker. These exacerbations generally did not occur immediately after their usage and therefore may have reflected other comorbidities in people with myasthenia gravis being treated with beta blockers. In a study of 20 people with myasthenia gravis treated with a beta blocker, 3 who received oral metoprolol, 9 who received intravenous metoprolol, 1 who received oral labetalol, and 9 who received intravenous labetalol, only one (i.e., 5%) of the 20 participants (who received intravenous labetalol) reacted with an exacerbation of myasthenia gravis symptoms.
1993/654) Rent Act 1977 (Forms etc.) (Amendment) Regulations 1993 (S.I. 1993/655) Rent Book (Forms of Notice) (Amendment) Regulations 1993 (S.I. 1993/656) Assured Tenancies and Agricultural Occupancies (Rent Information) (Amendment) Order 1993 (S.I. 1993/657) Local Government Finance (Housing) (Consequential Amendments) (Scotland) Order 1993 (S.I. 1993/658) Rent Assessment Committees (Scotland) (Consequential Amendments) Regulations 1993 (S.I. 1993/659) Child Support (Amendments to Primary Legislation) (Scotland) Order 1993 (S.I. 1993/660) A66 Trunk Road (Stainmore-Banks Gate De-Trunking) Order 1993 (S.I. 1993/661) A66 Trunk Road (Stainmore-Banks Gate Improvement) Order 1993 (S.I. 1993/662) County of Wiltshire (Electoral Arrangements) Order 1993 (S.I. 1993/679) M621 To M1 Link Roads (and Connecting Roads) Scheme 1993 (S.I. 1993/681) Nuclear Installations (Application of Security Provisions) Order 1993 (S.I. 1993/687) Council Tax Benefit (General) Amendment Regulations 1993 (S.I. 1993/688) Council Tax Benefit (Permitted Total) Order 1993 (S.I. 1993/689) Adoption (Designation of Overseas Adoptions) (Variation) Order 1993 (S.I. 1993/690) Cheshire, Lancashire and Merseyside (County and Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/691) War Pensions (Miscellaneous Amendments) Order 1993 (S.I. 1993/692) Guy's and St Thomas' National Health Service Trust (Establishment) Order 1993 (S.I. 1993/693) Lewisham Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/694) St Thomas' Hospital National Health Service Trust Dissolution Order 1993 (S.I.
Sources: en.wikipedia.org
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.
Hydrolysis, oxidation of susceptible residues, and aggregation all contribute, and their rates depend on pH, temperature, and concentration. Dissolved oxygen and trace metal ions accelerate oxidation. Keeping solutions cold, dilute, and free of unnecessary handling reduces these pathways.
Not always, because the value depends on the detection wavelength, the gradient, and how peak areas are integrated. A figure of ninety-eight percent from one laboratory may not mean the same as the same number from another. Comparing full chromatograms and mass spectra is more informative than comparing a single number.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.